BioVie Inc. Announces Closing of Registered Direct Offering Carson City, Nevada

Inc. Announces Closing of Registered Direct Offering

Carson City, Nevada, October 29, 2024 -

BioVie Inc. (Nasdaq: BIVI), ("BioVie" or the "Company"), a clinical-stage

company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative

disorders, today announced the closing of its previously announced registered direct offering of

1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share.

to the Company from the offering are $3,243,180, before deducting placement agent fees and offering expenses. The Company intends to use

the net proceeds from the offering primarily for working capital and general corporate purposes.

acted as sole placement agent for the offering.

The shares of common stock offered in the registered

direct offering were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-274083), including a base prospectus,

filed with the U.S. Securities and Exchange Commission (the "SEC") on August 18, 2023 and declared effective on August 28,

2023. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available

on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may

also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st

Floor, New York, New York 10004.

This press release shall not constitute an offer to

sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such

an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or

BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company

developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease

and Parkinson's disease) and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim

inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated

neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival).

Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation

are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company's Orphan drug candidate BIV201

(continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding

the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and

ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For

more information, visit www.bioviepharma.com.

Forward-Looking Statements

This press release contains forward-looking statements,

which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan,"

"believe," "seek," "estimate," "will," "project" or words of similar meaning. Although

BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations

will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability

to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations

that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval

for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions

as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed

from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual

reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking

statements), except as required by law.

For Investor Relations Inquiries:

Managing Director, LifeSci Advisors, LLC

For Media Relations Inquiries:

Managing Partner, Elixir Health Public Relations